SCHEMBL769739

SCHEMBL769739

CC[N+](CC)(CC)Cc1ccccc1.[N-]=[N+]=[N-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP1A2 P05177 1/20 0.45
CHRNA7 P36544 6/20 0.44
CHRNB4 P30926 5/20 0.44
CHRNA3 P32297 5/20 0.44
TP53 P04637 2/20 0.42
DNM1 Q05193 2/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CHRNB2 P17787 3/20 0.39
CHRNA4 P43681 3/20 0.39
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
HTT P42858 2/20 0.38
NPSR1 Q6W5P4 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27654815 0.98 KDM4E (0.45) KDM4EALDH1A1TDP1CYP1A2CHRNA7
SCHEMBL81238 0.91 KDM4E (0.54) KDM4EALDH1A1TDP1CYP1A2CHRNA7
Hydrogen Sulfide SCHEMBL5998579 0.91 KDM4E (0.54) KDM4EALDH1A1TDP1CYP1A2CHRNA7
Benzene SCHEMBL29130108 0.91 KDM4E (0.54) KDM4EALDH1A1TDP1CYP1A2CHRNA7
Bromide SCHEMBL653934 0.89 KDM4E (0.52) KDM4EALDH1A1TDP1CYP1A2CHRNA7
Hydrochloric Acid SCHEMBL80718 0.89 KDM4E (0.58) KDM4EALDH1A1TDP1CYP1A2CHRNA7
Bromide SCHEMBL117943 0.89 KDM4E (0.52) KDM4EALDH1A1TDP1CYP1A2CHRNA7
SCHEMBL990633 0.89 KDM4E (0.52) KDM4EALDH1A1TDP1CYP1A2CHRNA7
Hydrochloric Acid SCHEMBL7263491 0.89 KDM4E (0.58) KDM4EALDH1A1TDP1CYP1A2CHRNA7
SCHEMBL11224727 0.89 KDM4E (0.52) KDM4EALDH1A1TDP1CYP1A2CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210246108-A1 Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative TOKUYAMA CORPORATION (JP) 2021-08-12 US claimed
EP-3816151-A1 METHOD FOR PRODUCING ?-AZIDOANILINE DERIVATIVE OR ?, ?'-DIAZIDE DERIVATIVE Tokuyama Corporation (JP) 2021-05-05 EP claimed
CN-112262124-A Process for producing alpha-azidoaniline derivative or alpha, alpha' -diazide derivative 株式会社德山 2021-01-22 CN claimed
EP-1644395-B1 PROCESSES FOR PREPARING 4'AZIDO NUCLEOSIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-11-22 EP claimed
EP-1644395-A1 PROCESSES FOR PREPARING 4'AZIDO NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-04-12 EP claimed
US-20050038240-A1 Processes for preparing 4'-azido-nucleoside derivatives ROCHE PALO ALTO LLC 2005-02-17 US claimed
WO-2005000864-A1 PROCESSES FOR PREPARING 4’AZIDO NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO claimed
CN-117509571-A Method for continuously preparing iodine azide and application thereof 乐威医药(江苏)股份有限公司 2024-02-06 CN disclosed
US-20210246108-A1 Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative TOKUYAMA CORPORATION (JP) 2021-08-12 US disclosed
EP-3816151-A1 METHOD FOR PRODUCING ?-AZIDOANILINE DERIVATIVE OR ?, ?'-DIAZIDE DERIVATIVE Tokuyama Corporation (JP) 2021-05-05 EP disclosed
CN-112262124-A Process for producing alpha-azidoaniline derivative or alpha, alpha' -diazide derivative 株式会社德山 2021-01-22 CN disclosed
EP-2619215-B1 AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC (US) 2018-09-05 EP disclosed
EP-2752422-B1 Stereoselective synthesis of phosphorus containing actives GILEAD PHARMASSET LLC (US) 2017-08-16 EP disclosed
US-20110245484-A1 STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES PHARMASSET, INC. (US) 2011-10-06 US disclosed
EP-1644395-B1 PROCESSES FOR PREPARING 4'AZIDO NUCLEOSIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-11-22 EP disclosed
EP-1644395-A1 PROCESSES FOR PREPARING 4'AZIDO NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-04-12 EP disclosed
US-20050038240-A1 Processes for preparing 4'-azido-nucleoside derivatives ROCHE PALO ALTO LLC 2005-02-17 US disclosed
WO-2005000864-A1 PROCESSES FOR PREPARING 4’AZIDO NUCLEOSIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO disclosed
EP-0453642-A1 Glycidyl azide polymer (gap) synthesis by molten salt method ROCKWELL INTERNATIONAL CORPORATION (US) 1991-10-30 EP disclosed
US-5055600-A Azide treatment of polyepichlorohydrin with quaternary ammonium azide ions ROCKWELL INTERNATIONAL CORPORATION (US) 1991-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038240-A1 Processes for preparing 4'-azido-nucleoside derivatives NUDT1, RNGTT, DUT KDM4E 3974/4885ALDH1A1 920/4885TDP1 1725/4885
US-20110245484-A1 STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES PPA1, ENPP1, ITPA KDM4E 4417/4885ALDH1A1 2383/4885TDP1 2182/4885
US-20210246108-A1 Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative QDPR, AZI2, NISCH KDM4E 4043/4885ALDH1A1 50/4885TDP1 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.